Overview

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

Present trial is the third study that in combination with two completed studies (one being a trial in hepatic resection surgery also comparing TachoSil® and Surgicel® Original) targeted toward providing clinical safety and efficacy data to support extending the current label of TachoSil® to a general hemostasis indication across several surgical procedures and organ systems in the USA.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Collaborator:

Baxter Healthcare Corporation

Treatments:

Hemostatics